MiniMed Group Inc (NASDAQ:MMED) Given Consensus Rating of “Moderate Buy” by Analysts

MiniMed Group Inc (NASDAQ:MMED) has earned a consensus rating of “Moderate Buy” from the fifteen analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $21.3333.

Several analysts recently issued reports on the stock. William Blair assumed coverage on shares of MiniMed Group in a report on Tuesday, March 31st. They issued an “outperform” rating on the stock. Bank of America reduced their price objective on shares of MiniMed Group from $27.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, May 18th. The Goldman Sachs Group assumed coverage on shares of MiniMed Group in a report on Tuesday, March 31st. They issued a “buy” rating and a $24.00 price objective on the stock. Wall Street Zen upgraded shares of MiniMed Group to a “hold” rating in a report on Saturday, March 14th. Finally, Zacks Research upgraded shares of MiniMed Group to a “hold” rating in a report on Thursday, April 9th.

MiniMed Group Trading Down 2.0%

Shares of MiniMed Group stock opened at $15.16 on Friday. The company has a fifty day simple moving average of $12.91. MiniMed Group has a 52 week low of $10.65 and a 52 week high of $20.48.

MiniMed Group (NASDAQ:MMED) last issued its quarterly earnings data on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The company had revenue of $837.00 million for the quarter. MiniMed Group’s revenue was up 15.6% on a year-over-year basis.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.